Measures of Opioid-induced Hyperalgesia in Chronic Pain
beyond the scope of this review which focuses on patients who are maintained on long-term opioid therapy.
To determine whether clinical OIH exists and to characterize it, researchers have aimed at developing laboratory methods to measure hyperalgesia (i.e., the increase in pain sensitivity, as a proxy to clinical OIH) in chronic pain patients on long-term opioids, outside of the patient's primary clinical pain syndrome. To this end, laboratory methods have been developed that consist of evaluating patients' pain threshold and tolerance to external experimental stimuli such as mechanical (pressure, touch, or injection), thermal (cold/ heat), electrical, or other stimuli (e.g., ischemia). Two possible study designs have been typically used (1) patients with chronic pain on long-term opioids are cross-sectionally compared with patients with the same chronic pain syndrome not taking opioids, or (2) patients with chronic pain on long-term opioids are evaluated before and after an intervention such as discontinuing opioid therapy. However, none of these experimental approaches have been validated or is considered the definitive standard for measuring hyperalgesia in clinical trials of pain patients on chronic opioids. A suitable method for evaluating hyperalgesia would be reliable and responsive, that is, able to discriminate groups of patients known to have different levels of pain sensitivity that may be associated with opioid therapy. Therefore, we conducted a systematic review of clinical studies that incorporated measures of hyperalgesia in chronic pain patients on long-term opioids to determine and compare the performance of each method to measure hyperalgesia. Because responsiveness requires reliability, we have focused on responsiveness as the key performance characteristic for this review. Finding adequate experimental methods to measure hyperalgesia in chronic pain patients will help determine whether clinical OIH exist, to characterize it, and to prevent or treat it.
Materials and Methods

Literature Search
To find human studies that measure hyperalgesia in patients on long-term opioids for chronic pain, a search in PubMed and Cochrane databases was performed using terms ("all terms" search) such as "opioid induced hyperalgesia," "study or trial," and "long-term or chronic," and rejecting the terms "mice or rodent." A first screening of the retrieved articles was performed based on the title and abstract; the screened articles were then retrieved in their full version and carefully read to be included in the final selection. In order for an article to be selected, the study had to meet the following criteria: (1) be a randomized controlled trial, a prospective study, or a cross-sectional comparative study; (2) be conducted in patients on longterm opioids for chronic pain (single-dose/acute studies and studies conducted only in healthy volunteers were excluded); (3) include assessments or measures of hyperalgesia as part of the study; and (4) be published in English. The search included articles up to May 2014 (no date limit was used).
The methods used to measure hyperalgesia in the articles retrieved from the main search were compiled. To ensure that all possible original articles were found, a secondary literature search was conducted using the terms "opioid induced hyperalgesia" and the name of the test used to measure hyperalgesia (e.g., cold pressor test, thermal sensory analyzer, lidocaine injection, electrical stimulation, etc.).
Data Analysis
Data extracted from the articles included the type of study (studies were categorized into randomized controlled trials, prospective controlled studies, prospective uncontrolled studies, and cross-sectional comparative studies), the patient population, the measure(s)/test(s) used to assess hyperalgesia, available results (difference between pre-and posttreatment, difference between groups, dose-related data, and any other relevant data), and P values (when available).
Results
Search Results
The article screening and selection process is illustrated in figure 1 . The PubMed Library search retrieved 62 articles and the Cochrane database search retrieved 22; a search of our personal records retrieved 1 article. After elimination of duplicates, 68 articles were screened for relevance. A total of 11 articles made the final selection (from most to least recent): Suzan et al., 5 Chu et al., 6 Krishnan et al., 7 Edwards et al., 8 Wang et al., 9 Hooten et al., 10 Chen et al., 11 Ram et al. 12 Hay et al., 13 Cohen et al., 14 and Chu et al. 15 Searching the references of these articles retrieved two other articles (Reznikov et al. 16 [cited in Suzan et al. 5 ]; Doverty et al. 17 [cited in Chu et al. 6 ]). Another original article was found via the secondary search for OIH and lidocaine injection (Kim et al. 18 ). Thus, a total of 14 original studies that measured hyperalgesia in patients on long-term opioids for chronic pain were found.
Description of Studies
Of the 14 selected studies, 1 was a randomized controlled trial, 6 1 was a prospective controlled study, 5 3 were prospective uncontrolled studies, 9,10,15 and 9 were cross-sectional observation studies. 7, 8, [11] [12] [13] [14] [16] [17] [18] Six hyperalgesia measurement paradigms were used in these studies: cold pain, heat pain, pressure pain, electrical pain, ischemic pain, and injection pain; these methods are described in table 1. The design, patient population, and results of each study are summarized in table 2.
Summary of Findings
The ideal measure would be able to differentiate pain sensitivity in patients randomly exposed prospectively to opioids compared with a cohort randomly assigned to a control condition. Only one study 6 used such a design (randomized controlled trial), and the two experimental methods used in that study (cold pain threshold and tolerance using ice water Cold pain Cold pressor test The subject's hand is submerged up to the wrist in a 0.5°-1°C ice water bath continuously recirculated by a pump (up to 120 s). Measures are time to pain detection (threshold) and to intolerable pain (withdrawal of the hand; tolerance); continuous pain scores. Painful cold water immersion was used as the conditioning stimulus in a CPM paradigm.
Chu et al., 15 Chu et al., 6 Hay et al., 13 Suzan et al. 5 Heat pain Medoc TSA (Medoc Ltd. Advanced Medical Systems, Ramat Yishai, Israel)
Quantitative pain threshold is determined with the method of limits with the Medoc TSA. A thermode is applied to the skin and heat is applied at various temperatures. Measures are pain threshold and pain tolerance (in °C); pain scores at various temperatures; temporal summation of suprathreshold heat stimuli (in a few studies); ratings of heat pain intensity used as the test stimulus in a CPM paradigm.
Reznikov et al., 16 Chu et al., 15 Chu et al., 6 Suzan et al., 5 Chen et al., 11 Edwards et al. 8 Pressure pain
Pressure algometer
A manual pressure algometer (e.g., a 3-mm diameter paddle algometer; Medical-Hako, Hamburg, Germany) is pressed perpendicularly to the skin at selected points and increasing pressure is applied. Measures are time to perception of a painful sensation (threshold); the measurement is shown on an algometer scale.
Reznikov et al. 16 Electrical pain
Electrical stimulation of ear lobe
Voltage is applied to ear lobe starting at 0 V and increasing at a constant rate of 2 V every 1.4 s, up to a maximum of 100 V. Measures are pain threshold and pain tolerance (in volts).
Doverty et al., 17 Krishnan et al., 7 Hay et al. 13 
Ischemic pain
Blood pressure cuff test with handgrip exercise A blood pressure cuff is placed around the nondominant arm of the subject and the pressure is increased to 20 mmHg above the subject's systolic pressure. With the pressure maintained, subjects perform a handgrip exercise on an elastic ball, in accordance with the rhythm of a metronome (subject's eyes are covered to minimize distraction and time cues).
Measures are time to feeling of pain (pain threshold); time to untolerable pain (to a maximum of 5 min) (pain tolerance).
Krishnan et al., 7 Ram et al. 12 Injection pain
Subcutaneous local anesthetic injection
A local anesthetic (generally lidocaine) is administered subcutaneously (before a full dose of anesthetic for a procedure). Measures are subject's ratings of pain and unpleasantness of the lidocaine injection. Measures of Opioid-induced Hyperalgesia in Chronic Pain tained-release morphine (n = 69) or placebo (n = 70) for 1 mo. Patients subjected to a target-controlled infusion with the opioid agonist remifentanil or saline. Cold pain: Patients in the morphine group had significant changes in pain threshold from baseline (P = 0.005). There were no significant changes from baseline in tolerance in both groups. There were no significant differences in the changes for threshold and tolerance between the two groups.
Heat pain: Patients in each treatment group had significant changes in pain threshold from baseline (P = 0.05 for morphine group; P = 0.006 for placebo group). There were no significant changes from baseline in tolerance in both groups. There were no significant differences in the changes in pain threshold and tolerance between groups.
Chu et al. 6 Prospective controlled (nonrandomized) studies Prospective uncontrolled studies (from most to less recent) Heat/cold pain Thermal Sensory Analyzer (Medoc) Patients with LBP taking opioids (n = 35) being tapered off; patients with LBP not taking opioids (n = 35); healthy controls (n = 28) Parameters measured: cold and heat pain threshold in low back and nondominant hand before (T1), and 3 wk (T2) and 6 mo postopioid tapering (T3). Opioid patients were off opioids by T2 and remained off at T3.
Heat pain intensity
Heat pain thresholds: Opioid patients had lower heat pain thresholds than controls at all time points (T1, P = 0.007; T2, P = 0.007; T3, P = 0.017). Nonopioid patients had lower heat pain threshold than controls at T1 (P = 0.001) and T2 (0.002). At T3, heat pain thresholds of nonopioid patients normalized. There was no difference between opioid and nonopioid patients at any time point. Cold pain thresholds: Opioid patients had lower threshold to cold stimuli than nonopioid patients (P = 0.004 for hand) and controls (P = 0.001 for hand, P = 0.021 for left low back). Nonopioid patients had a cold pain threshold similar to controls.
Wang et al. 9 Heat pain Standardized QST: automated Computer Aided Sensory Evaluator IV Patients (n = 109) taking opioids admitted to a multidisciplinary pain rehabilitation program which includes opioid tapering over 3 wk.
(QST performed before and after taper). Greater baseline morphine dose was associated with lower or more hyperalgesic values of HP 5-0.5 † (P = 0.040). Tapering of greater morphine doses was associated with lower values of HP 5-0.5 † (P = 0.001).
Hooten et al. 10 Cold pain Heat pain Cold pressor test Thermal Sensory Analyzer (Medoc) Patients (n = 6) with LBP taking morphine assessed before and 1 mo after treatment. Cold pain: Patients developed significant hyperalgesia to cold pressor pain after 1 mo of oral morphine therapy (P < 0.01). Pain threshold dropped by approximately 16% (from 12.1 ± 4.1 to 10.1 ± 3.7 s), and pain tolerance dropped by approximately 24% (from 28.0 ± 13.7 to 19.8 ± 6.0 s).
Heat pain: Heat pain threshold did not change significantly between sessions (−0.2° ± 0.6°C).
Chu et al. 15 (Continued)
PAIN MEDICINE
Cross-sectional comparative studies (from most to less recent)
Injection
Subcutaneous injection of LA Patients taking opioids (n = 62); patients not taking opioids (n = 20). LA injection-specific pain score, unpleasantness, and behavior pain score are higher in opioid patients (at any dose) vs. nonopioid patients (P < 0.01). In nonopioid patients, postinjection pain scores, unpleasanteness, and behavioral pain score were higher in patients taking high dose (≥200 mg) than those taking low doses (1-59 mg) (P < 0.05). taking low-dose opioids (n = 88); high-dose opioids (n = 91); or no opioids (n = 97). Mechanical pain: No significant differences between groups in mechanical pain sensitivity.
Pressure pain: No significant differences between groups in pressure pain sensitivity.
Heat pain: No significant differences between groups in (cold/warm) thermal sensitivity.
Edwards et al. 8 Heat pain Mechanical pain Thermal Sensory Analyzer (Medoc)
Von Frey filaments Pinprick Chronic pain patients taking opioids (n = 58); chronic pain patients not taking opioids (n = 41); controls: healthy volunteers not taking opioids (n = 41). Heat pain: Statistically significant differences were detected among three groups in heat pain threshold (P = 0.02), cold pain tolerance (P = 0.01), heat pain tolerance (P = 0.01), and duration of tolerance to the suprathreshold heat stimulation (P = 0.02). Post hoc analysis showed significant differences in these four parameters between opioid patients and controls (P < 0.05) but not between nonopioid patients and controls. The degree of temporal summation of the second pain was significantly exacerbated in opioid patients vs. nonopioid patients and controls (P < 0.05) (no differences between nonopioid patients and controls doses of methadone and matched control subjects (n = 16). Cold pain: Meth patients detected pain significantly earlier than controls at 0 h and were also much less pain tolerant than controls at 0 and 3 h. No significant differences in pain detection values between groups at 3 h. Pain tolerance/pain detection ratios for Meth patients were significantly lower than controls at 0 and 3 h. Electrical pain: Meth patients' pain tolerance values were lower than controls at 0 h, but higher than controls at 3 h; no significant differences in pain detection values were found. Pain tolerance/pain detection ratios for Meth patients were significantly lower than controls at 0 h only. * Refer to table 1 for test description. † Measurements are based on the method of levels. Heat pain perception (HP 5, HP 0.5, and HP 5-0.5) are calculated. HP 0.5 is the midpoint between a nonpainful stimulus and the least stimulus magnitude necessary to elicit pain; thus, HP 0.5 is a measure of HP threshold. HP 5 is the stimulus magnitude necessary to elicit a pain rating of 5 from the subject; thus, HP 5 is considered to be a measure of intermediately intense pain. HP 5-0.5 is a measure of the slope of the line connecting these two points, and this HP parameter has been termed the pain-stimulus response slope. − indicates a negative finding. ± indicates an equivocal finding (studies with ± findings are not taken into account in the total of negative and positive studies). For pre-post comparisons, a "+" indicates that patients on opioids are more sensitive to pain after long-term opioid treatment, as assessed by the test (or that tapering of opioid significantly decreases pain sensitivity). For group comparisons, a "+" indicates that patients on opioids are more sensitive to pain than patients not on opioids, as assessed by the test. † Von Frey filaments, pinprick, or algometry. CPM = conditioned pain modulation; RCT = randomized controlled trial.
immersion and heat pain threshold and tolerance using the Medoc TSA; Medoc Ltd. Advanced Medical Systems, Ramat Yishai, Israel) both failed to differentiate the two groups. It is unclear whether these approaches failed because of the measures, because the patients did not in fact develop hyperalgesia, or because treatment was short term and used relatively low doses. Thus, no measure of hyperalgesia can claim definitive standard status. Table 3 summarizes the test results by indicating which measures were used in each study, and whether the P value for the between-group difference tested was greater than 0.05 (−) or less than 0.05 (+). The major methods that have been used are (1) cold pain threshold and tolerance using ice water immersion, and (2) heat pain threshold, tolerance, or intensity at suprathreshold stimulus levels using computercontrolled thermode devices. The summary results in table 3 suggest that, on average, none of the stimuli were capable of detecting hyperalgesia in chronic pain patients on long-term opioids. However, some specific findings merit attention. For instance, two controlled prospective studies 5, 6 and one uncontrolled prospective study 10 found a significant difference in heat pain sensitivity between pre-and postopioid treatment.
Discussion
This systematic review was conducted to determine and compare the responsiveness of methods to measure hyperalgesia in clinical studies of chronic pain patients on long-term opioids. Fourteen articles reporting original studies measuring hyperalgesia in those patients were retrieved. Because clinical OIH has not yet been definitively demonstrated, it is not possible to directly determine the responsiveness of measures of this phenomenon. Furthermore, the studies performed in this area tend to have small sample sizes, different experimental designs, and different testing protocols, thereby precluding formal meta-analytic methods. The summary results in table 3 suggest that, on average, none of the stimuli have sufficient power to detect hyperalgesia in chronic pain patients on long-term opioids. However, some specific findings merit attention. For instance, it is notable that three prospective studies that assessed heat pain ratings reported heat hyperalgesia when patients were on opioid therapy (compared with when they were off opioids). 5, 6, 10 Although a larger number of studies have been performed with ice water immersion, a substantial proportion of these studies failed to discriminate "known" groups, and the aversive nature of the test should be considered. Mechanical testing approaches (algometry or von Frey filaments) have been used several times, never successfully. 7, 8, 11, 13, 16 Other approaches (conditioned pain modulation, ischemia, injection pain) have been unsuccessful, inconsistent, or have been used too rarely to conclude. 7, 8, 12, 14, 18 Thus, this review failed to identify a definitive standard for hyperalgesia measures. This is mainly due to the fact that the measurements failed to detect a change because the measures are not sensitive enough, the sample is too small for the measure to detect change, the studies use suboptimal study designs (most being cross-sectional), and/or the timing of opioid dosing was not controlled for. Moreover, all these studies provide averages of hyperalgesia variables over the entire group of opioid-treated patients, which may obliterate the phenomenon if the development of hyperalgesia is a rare occurrence in patients on opioids. Therefore, clinicians who wish to conduct a clinical trial to measure hyperalgesia in opioid-treated patients should choose a randomized controlled trial design and report the proportion of patients on opioids who develop hyperalgesia during the treatment. Finally, although most studies focused on measure responsiveness, assessing reliability and other forms of validity would also be informative. This review identified heat stimuli (using the Medoc TSA; Medoc Ltd. Advanced Medical Systems) as a potentially good candidate for further testing in future studies. More data should also be generated with injection pain to determine whether this method holds true potential.
Importantly, clinicians should be cautious not to take the increase in pain sensitivity (hyperalgesia) to experimental stimuli as a proof of OIH in opioid-treated patients. Indeed, clinical OIH is a syndrome that has three main symptoms: one of them being an increase in pain sensitivity to external stimuli and the other two being an increase in pain intensity over time and the spreading of pain to other locations. To conclude that a patient experiences OIH should rely on additional evaluation of the patient's clinical data and medical history to determine whether all characteristics of clinical OIH are present. To this end, Chen et al. 11 provides a list of clinical factors that should be taken into account in the diagnosis of clinical OIH.
